Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non-small-cell lung cancer.
Aged
Biomarkers, Tumor
/ blood
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Cohort Studies
Disease Progression
ErbB Receptors
/ antagonists & inhibitors
Erlotinib Hydrochloride
/ administration & dosage
Female
Follow-Up Studies
Humans
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Neoplasm Metastasis
Protein Kinase Inhibitors
/ administration & dosage
Retrospective Studies
Treatment Outcome
Uric Acid
/ blood
erlotinib
lung cancer
uric acid
Journal
Journal of clinical pharmacy and therapeutics
ISSN: 1365-2710
Titre abrégé: J Clin Pharm Ther
Pays: England
ID NLM: 8704308
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
13
05
2019
revised:
01
10
2019
accepted:
18
10
2019
pubmed:
30
11
2019
medline:
15
12
2020
entrez:
29
11
2019
Statut:
ppublish
Résumé
Erlotinib is a small molecule tyrosine kinase inhibitor which blocks the activation of epidermal growth factor receptor (EGFR), a transmembrane receptor that is upregulated in many cancer types. Inhibition of angiogenesis with consequent impairments in intratumoral microcirculation is one of the mechanisms through which EGFR inhibition halts the progression of cancer. A consequence of impaired microcirculation is intratumoral hypoxia, which results in increases in serum uric acid levels. The goal of this study was to investigate the relationship between serum uric acid levels and response to erlotinib in metastatic non-small-cell lung cancer (NSCLC). A total of 56 patients with metastatic non-small-cell lung cancer who received erlotinib for a duration of at least 3 months were included in this retrospective cohort study. Demographic characteristics, progression status, baseline serum uric levels and 3-month serum uric acid levels were recorded and analysed. Of the study population, 21 (37.5%) were female and 35 (62.5%) were male patients. No significant difference in above demographic characteristics was observed among exitus, survivor with progression and survivor without progression groups. Patients who responded favourably to erlotinib with no progression of their disease had significantly increased uric acid levels at 3-month follow-up (P = .01). Such a correlation was not observed if the patient was exitus (P = .47) or had progressed on erlotinib therapy (P = .19). In conclusion, this study is the first to demonstrate significant increases in serum uric acid levels in patients with metastatic NSCLC who responded favourably to erlotinib and had no progression under erlotinib therapy. Further studies are required to confirm and characterize serum uric acid as a novel biomarker in predicting the outcome in those with metastatic NSCLC.
Substances chimiques
Biomarkers, Tumor
0
Protein Kinase Inhibitors
0
Uric Acid
268B43MJ25
Erlotinib Hydrochloride
DA87705X9K
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
303-308Subventions
Organisme : Republic of Turkey Ministry of Development
Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Ray M, Salgia R, Vokes EE. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist. 2009;14(11):1116-1130.
Ji QS, Winnier GE, Niswender KD, et al. Essential role of the tyrosine kinase substrate phospholipase C-gamma1 in mammalian growth and development. Proc Natl Acad Sci USA. 1997;94(7):2999-3003.
Liao HJ, Kume T, McKay C, Xu MJ, Ihle JN, Carpenter G. Absence of erythrogenesis and vasculogenesis in Plcg1-deficient mice. J Biol Chem. 2002;277(11):9335-9341.
Tai SC, Robb GB, Marsden PA. Endothelial nitric oxide synthase: a new paradigm for gene regulation in the injured blood vessel. Arterioscler Thromb Vasc Biol. 2004;24(3):405-412.
Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 2017;9(5):E52.
Singh M, Jadhav HR. Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors. Drug Discov Today. 2018;23(3):745-753.
Zhang YL, Yuan JQ, Wang KF, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993.
Oizumi S, Kobayashi K, Inoue A, et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist. 2012;17(6):863-870.
Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154-162.
Mazzoni F, Rotella V, Pratesi N, et al. From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy. Tumori J. 2011;97(2):160-165.
Selcukbiricik F, Kanbay M, Solak Y, et al. Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer. Clin Transl Oncol. 2016;18(11):1082-1087.
Kanbay M, Ikizek M, Solak Y, et al. Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease. Am J Nephrol. 2011;33(4):325-331.
Kanbay M, Solak Y, Dogan E, Lanaspa MA, Covic A. Uric acid in hypertension and renal disease: the chicken or the egg? Blood Purif. 2010;30(4):288-295.
Hahn K, Kanbay M, Lanaspa MA, Johnson RJ, Ejaz AA. Serum uric acid and acute kidney injury: a mini review. J Adv Res. 2017;8(5):529-536.
Kanbay A, Inonu H, Solak Y, et al. Uric acid as a potential mediator of cardiovascular morbidity in obstructive sleep apnea syndrome. Eur J Intern Med. 2014;25(5):471-476.
Kanbay M, Yilmaz MI, Sonmez A, et al. Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. Am J Nephrol. 2011;33(4):298-304.
Kanbay M, Solak Y, Afsar B, et al. Serum uric acid and risk for acute kidney injury following contrast. Angiology. 2017;68(2):132-144.
Mendi MA, Afsar B, Oksuz F, et al. Uric acid is a useful tool to predict contrast-induced nephropathy. Angiology. 2017;68(7):627-632.
Kanbay M, Jensen T, Solak Y, et al. Uric acid in metabolic syndrome: from an innocent bystander to a central player. Eur J Intern Med. 2016;29:3-8.
Kanbay M, Siriopol D, Nistor I, et al. Effects of allopurinol on endothelial dysfunction: a meta-analysis. Am J Nephrol. 2014;39(4):348-356.
Gullu H, Erdogan D, Caliskan M, et al. Elevated serum uric acid levels impair coronary microvascular function in patients with idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2007;9(5):466-468.
Yuan Y, Ikram MK, Jiang S, et al. Hyperuricemia accompanied with changes in the retinal microcirculation in a Chinese high-risk population for diabetes. Biomed Environ Sci. 2011;24(2):146-154.
Wijnands JM, Houben AJ, Muris DM, et al. Uric acid and skin microvascular function: the Maastricht study. J Hypertens. 2015;33(8):1651-1657.
Patschan D, Patschan S, Gobe GG, Chintala S, Goligorsky MS. Uric acid heralds ischemic tissue injury to mobilize endothelial progenitor cells. J Am Soc Nephrol. 2007;18(5):1516-1524.
Plank MS, Calderon TC, Asmerom Y, Boskovic DS, Angeles DM. Biochemical measurement of neonatal hypoxia. J Vis Exp. 2011;(54);2948.
Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27( suppl 5):v1-v27.
Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol. 2011;6(8):1887-1894.
Oh CM, Park SK, Ryoo JH. Serum uric acid level is associated with the development of microalbuminuria in Korean men. Eur J Clin Invest. 2014;44(1):4-12.
Matheus AS, Tibirica E, da Silva PB, de Fatima Bevilacqua da Matta M, Gomes MB. Uric acid levels are associated with microvascular endothelial dysfunction in patients with type 1 diabetes. Diabet Med. 2011;28(10):1188-1193.
Kanbay M, Sanchez-Lozada LG, Franco M, et al. Microvascular disease and its role in the brain and cardiovascular system: a potential role for uric acid as a cardiorenal toxin. Nephrol Dial Transplant. 2011;26(2):430-437.
Solak Y, Akilli H, Kayrak M, et al. Uric acid level and erectile dysfunction in patients with coronary artery disease. J Sex Med. 2014;11(1):165-172.
Aribas A, Kayrak M, Ulucan S, et al. The relationship between uric acid and erectile dysfunction in hypertensive subjects. Blood Press. 2014;23(6):370-376.
Lanza GA, Crea F. Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management. Circulation. 2010;121(21):2317-2325.
Xia S, Deng SB, Wang Y, et al. Clinical analysis of the risk factors of slow coronary flow. Heart Vessels. 2011;26(5):480-486.
Braga TT, Forni MF, Correa-Costa M, et al. Soluble uric acid activates the NLRP3 inflammasome. Sci Rep. 2017;7:39884.